Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hair Loss
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hair Loss
    TopAbstracts in Hair Loss 10/19/2009 - (DGNews)
    TopAbstracts in Hair Loss 09/21/2009 - (DGNews)
    TopAbstracts in Hair Loss 08/24/2009 - (DGNews)
    TopAbstracts in Hair Loss 07/27/2009 - (DGNews)
    TopAbstracts in Hair Loss 06/29/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Hair Loss
      Cutaneous Metastasis of Breast Carcinoma Presenting as Alopecia Neoplastica

      Webcasts/CME archive

       Recent cases - Hair Loss
        Sudden Hair Loss Associated with Trachyonychia
        Lipedematous Alopecia of the Scalp
        Alopecia Areata in Darier Disease and Clinical Findings in Five Affected Family Members
        Frontal Fibrosing Alopecia
        Alopecia Areata of Eyelashes: A Subset of Alopecia Areata

        Cases archive
          




        my personal edition > hair loss > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Hormones Influence Efficacy Of Treatment For Women's Alopecia

        A DGReview of :"Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial"
        British Journal of Dermatology

        07/12/2002
        By David Loshak


        The effectiveness of minoxidil compared to cyproterone in treating female alopecia depends on whether or not body mass index is high or if biochemical hyperandrogenism is present, suggests a study from France.

        Minoxidil was more effective in the absence of other signs of hyperandrogenism, hyperseborrhoea and menstrual cycle modifications when the body mass index was low and nothing argued in favour of biochemical hyperandrogenism.

        But, when other signs were present and when the body mass index was high - factors which pointed to a diagnosis of biochemical hyperandrogenism - cyproterone acetate treatment was more effective, report specialists in Paris.

        They noted that although hormone studies had shown the androgen-dependent character of female androgenetic alopecia, there had been few controlled studies of therapies for alopecia in women.

        To compare topical minoxidil and cyproterone acetate in the treatment of this condition, the specialists randomised 66 women with female-pattern alopecia into two equal groups for 12 menstrual cycles.

        One group received two local applications of topical minoxidil 2.0 percent 2.0 mL/day -1 plus combined oral contraceptive. The other group received cyproterone acetate 52 mg/day -1 plus ethinyl oestradiol 35 µg for 20 of every 28 days.

        There was a mean reduction of 2.4 ± 6.2 per 0.36 cm² in hairs of diameter >40 µm in the cyproterone acetate group and a mean increase of 6.5 ± 9.0 per 0.36 cm² in the minoxidil group.

        Comparison of the total number of hairs at 12 months and the body mass index showed a borderline positive correlation in the cyproterone acetate group and a negative correlation in those who received minoxidil.

        There was no significant difference in the total number of hairs among cyproterone acetate patients according to the presence or absence of other symptoms of hyperandrogenism. With minoxidil, on the other hand, the total number of new hairs was higher in patients with isolated alopecia.

        Variations in scalp seborrhoea were significant in both groups. The result was better - for acne and hirsutism as well - with cyproterone acetate than minoxidil.
        British Journal of Dermatology 2002; 146 (6), 992-999. "Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send